国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2013年
12期
2452-2455
,共4页
王晓波%吴国基%张雪岩%罗向东%刘丛
王曉波%吳國基%張雪巖%囉嚮東%劉叢
왕효파%오국기%장설암%라향동%류총
视网膜分支静脉阻塞%黄斑水肿%雷珠单抗%激光光凝
視網膜分支靜脈阻塞%黃斑水腫%雷珠單抗%激光光凝
시망막분지정맥조새%황반수종%뢰주단항%격광광응
branch retinal vein occlusion%macular edema%ranibizumab%laser photocoagu-lation
目的:观察玻璃体腔注射雷珠单抗联合黄斑区格栅样光凝治疗视网膜分支静脉阻塞( branch retinal vein occlusion BRVO)继发黄斑水肿的疗效和安全性。<br> 方法:据荧光素眼底血管造影( FFA)对30例30眼视网膜分支静脉阻塞继发黄斑水肿患者随机分为2组:第1组(14眼)单纯行黄斑区格栅样光凝( GLP);第2组(16眼)玻璃体腔连续注射3次雷珠单抗0.05mL/(0.5mg),每次间隔1mo,第1次注射雷珠单抗7d后行GLP治疗。随访6mo,观察最佳矫正视力( BCVA)及光学相关断层扫描( OCT)检查黄斑中心凹厚度( CMT)的变化。<br> 结果:治疗6 mo后两组患者最佳矫正视力( BCVA )均提高,联合治疗组优于单纯GLP组( P<0.05)。 OCT显示第1组黄斑中心凹厚度平均降低236.4±113.0μm,第2组平均降低386.6±195.5μm,联合治疗组优于单纯GLP组(P<0.05)。<br> 结论:联合治疗的效果明显优于单纯GLP治疗的效果,玻璃体腔内注射雷珠单抗联合黄斑区格栅样光凝术治疗视网膜分支静脉阻塞继发黄斑水肿安全有效。
目的:觀察玻璃體腔註射雷珠單抗聯閤黃斑區格柵樣光凝治療視網膜分支靜脈阻塞( branch retinal vein occlusion BRVO)繼髮黃斑水腫的療效和安全性。<br> 方法:據熒光素眼底血管造影( FFA)對30例30眼視網膜分支靜脈阻塞繼髮黃斑水腫患者隨機分為2組:第1組(14眼)單純行黃斑區格柵樣光凝( GLP);第2組(16眼)玻璃體腔連續註射3次雷珠單抗0.05mL/(0.5mg),每次間隔1mo,第1次註射雷珠單抗7d後行GLP治療。隨訪6mo,觀察最佳矯正視力( BCVA)及光學相關斷層掃描( OCT)檢查黃斑中心凹厚度( CMT)的變化。<br> 結果:治療6 mo後兩組患者最佳矯正視力( BCVA )均提高,聯閤治療組優于單純GLP組( P<0.05)。 OCT顯示第1組黃斑中心凹厚度平均降低236.4±113.0μm,第2組平均降低386.6±195.5μm,聯閤治療組優于單純GLP組(P<0.05)。<br> 結論:聯閤治療的效果明顯優于單純GLP治療的效果,玻璃體腔內註射雷珠單抗聯閤黃斑區格柵樣光凝術治療視網膜分支靜脈阻塞繼髮黃斑水腫安全有效。
목적:관찰파리체강주사뢰주단항연합황반구격책양광응치료시망막분지정맥조새( branch retinal vein occlusion BRVO)계발황반수종적료효화안전성。<br> 방법:거형광소안저혈관조영( FFA)대30례30안시망막분지정맥조새계발황반수종환자수궤분위2조:제1조(14안)단순행황반구격책양광응( GLP);제2조(16안)파리체강련속주사3차뢰주단항0.05mL/(0.5mg),매차간격1mo,제1차주사뢰주단항7d후행GLP치료。수방6mo,관찰최가교정시력( BCVA)급광학상관단층소묘( OCT)검사황반중심요후도( CMT)적변화。<br> 결과:치료6 mo후량조환자최가교정시력( BCVA )균제고,연합치료조우우단순GLP조( P<0.05)。 OCT현시제1조황반중심요후도평균강저236.4±113.0μm,제2조평균강저386.6±195.5μm,연합치료조우우단순GLP조(P<0.05)。<br> 결론:연합치료적효과명현우우단순GLP치료적효과,파리체강내주사뢰주단항연합황반구격책양광응술치료시망막분지정맥조새계발황반수종안전유효。
AIM: To compare the safety and efficacy of intravitreal injection with ranibizumab combined with grid laser photocoagulation for the treatment of macular edema secondary to branch retinal vein occlusion ( BRVO) . <br> METHODS: Thirty patients ( 30 eyes ) with BRVO were randomized into two groups:Group 1 (14 eyes) received grid laser photocoagulation ( GLP ) treatment alone, Group 2 (16 eyes) received three loading doses 0.05mL/(0.5mg ) of intravitreal injection with ranibizumab at monthly interval ( i.e.0, 1 month and 2 months ) plus standard laser treatment 7d after the 1st injection.During the 6 months of follow-up, observation was made on the changes of the best-corrected visual acuity ( BCVA) and central macular thickness ( CMT) by OCT. <br> RESULTS: After 6 months follow-up, the patients'BCVA in two groups were both improved with the combined treatment group better than the simple GLP group ( P<0.05 ); OCT display that CMT of group 1 decreased by an average of 236.4 ±113.0μm, CMT of group 2 decreased by an average of 386.6 ±195.5μm with the combined treatment group better than the simple GLP group (P<0.05). <br> CONCLUSION:The effect of the combined treatment is better than that of the simple GLP treatment.Intravitreal injection with ranibizumab combined with grid laser photocoagulation for the treatment of macular edema secondary to branch retinal vein occlusion is effective and safe.